HJLI | tickerfilter.com

Fundamental analysis

27%

Profitability 33%

Dept financing 25%

Liquidity 11%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.34%

1 Month

31.73%

3 Months

51.09%

6 Months

55.86%

1 Year

-4.11%

2 Year

-51.40%

Key data

Stock price

$10.24

P/E Ratio

0.00

DAY RANGE

$10.24 - $10.75

EPS

$0.00

52 WEEK RANGE

$4.99 - $17.68

52 WEEK CHANGE

-$0.05

MARKET CAP

88.931 M

YIELD

N/A

SHARES OUTSTANDING

8.685 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$279,119

AVERAGE 30 VOLUME

$295,753

Company detail

CEO:
Region: US
Website: www.hancockjaffe.com
Employees: 19
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

HJLI - Hancock Jaffe Laboratories Inc